Targeted therapy: resistance and re-sensitization

Cancer Communications

Dao-Hong Chen³  Xiao-Shi Zhang⁴ 

[1] Collaborative Innovation Center for Cancer Medicine, Guangzhou, P. R. China;State Key Laboratory of Oncology in South China;Biomedical Research Institute, Yiling Pharmaceutical Company, Beijing, P. R. China;Biotherapy Center, Sun Yat-sen University Cancer Center

关键词: Targeted therapy;    Drug resistance;    Re-sensitization;   

DOI  :  10.1186/s40880-015-0047-1

学科分类：肿瘤学

来源: Springer

【 摘 要 】

The last two decades have witnessed a paradigm shift from cytotoxic drugs to targeted therapy in medical oncology and pharmaceutical innovation. Inspired by breakthroughs in molecular and cellular biology, a number of novel synthesized chemical compounds and recombinant antibodies have been developed to selectively target oncogenic signaling pathways in a broad array of tumor types. Although targeted therapeutic agents show impressive clinical efficacy and minimized adverse effects compared with traditional treatments, the challenging drug-resistant issue has also emerged to limit their benefits to cancer patients. In this regard, we aim to improve targeted therapy by presenting a systematic framework regarding the drug resistance mechanisms and alternative approaches to re-sensitize cancer cells/tissues therapeutically.

【 授权许可】

CC BY